Loading
Wilms tumour is staged I to V from the scans and the operation together: from a tumour removed whole inside the kidney (I), through spread in the abdomen (III) and distant spread (IV), to both kidneys involved (V).
The NCI's health professional summary gives the staging system developed by the National Wilms Tumor Study Group and still used by the Children's Oncology Group, which combines imaging with surgical and pathological findings; the histology (favourable or anaplastic) is stated alongside the stage. Stage I (43% of patients): limited to the kidney, completely removed, capsule intact, not ruptured or biopsied beforehand, nodes negative. Stage II (20%): extends beyond the kidney but completely removed with clear margins. Stage III (21%): tumour left in the abdomen after surgery, including involved abdominal or pelvic nodes, peritoneal spread, rupture or spill, biopsy before removal, or removal in more than one piece. Stage IV (11%): spread through the blood (lung, liver, bone, brain) or to nodes outside the abdomen and pelvis. Stage V (5%): both kidneys at diagnosis. Lymph node sampling is strongly recommended for all patients, even when the nodes look normal.
Renal cell carcinoma comes from the kidney's filtering cortex, urothelial cancer from the lining of the collecting system and bladder, and the adrenal on top hosts cortical and medullary (neuroblastoma) tumours.
Same organ: Collecting duct carcinoma of the kidney, Renal medullary carcinoma (SMARCB1-deficient), TFE3-rearranged (translocation) renal cell carcinoma, Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated), Succinate dehydrogenase-deficient renal cell carcinoma, Mucinous tubular and spindle cell carcinoma of the kidney, Eosinophilic solid and cystic renal cell carcinoma, Clear cell papillary renal cell tumour, Urothelial carcinoma of the urethra, Squamous cell carcinoma of the urethra, Adenocarcinoma of the urethra (including clear cell adenocarcinoma), Melanoma of the urethra, Non-muscle-invasive bladder cancer, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Clear cell renal cell carcinoma, Papillary renal cell carcinoma, Chromophobe renal cell carcinoma, Renal cell carcinoma, Neuroblastoma (paediatric), Low-risk neuroblastoma (INRG very low and low risk, including stage MS), Intermediate-risk neuroblastoma, High-risk neuroblastoma, Adrenocortical carcinoma, Pheochromocytoma and paraganglioma (PPGL), Urethral cancer, Penile cancer, Localised penile cancer (organ-confined, node-negative), Node-positive and metastatic penile cancer, Localised adrenocortical carcinoma (ENSAT stage I to III, resectable), Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable), Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127), Metastatic pheochromocytoma and paraganglioma
Showing the organ this term concerns: Wilms tumour (nephroblastoma).
Shares Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups), Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC).
Shares Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups), Wilms tumour (nephroblastoma).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/